Neuroendocrine Tumor Overview

Save information for later
Sign Up

Learn About Neuroendocrine Tumor

What is the definition of Neuroendocrine Tumor?
Neuroendocrine tumors are rare cancers that grow from neuroendocrine cells. Neuroendocrine cells receive signals from the nervous system to release hormones. There are several types of neuroendocrine tumors, although most occur in the lungs, pancreas, adrenal glands, small intestine, appendix, and rectum. Neuroendocrine tumors may also spread to the lymph nodes, liver, or bones.
What are the symptoms of Neuroendocrine Tumor?
Symptoms of a neuroendocrine tumor depend on the tumor’s location and whether it is producing excess hormones. Symptoms of neuroendocrine tumors may include pain, a lump under the skin, fatigue, persistent cough or hoarseness, unexplained weight loss, confusion, anxiety, dizziness, shakiness, elevated blood glucose, low blood glucose, an ulcer, skin flushing, skin rash, increased thirst, nausea and vomiting, diarrhea, and carcinoid syndrome. Carcinoid syndrome is a condition that occurs when a neuroendocrine tumor produces excess hormones. Symptoms of carcinoid syndrome include skin flushing of the head and neck; sweating; shortness of breath; wheezing; rapid heartbeat; heart murmur; high blood pressure; yellowing of the skin and eyes; abdominal cramping; diarrhea; greasy, foul-smelling bowel movements; and swelling of the feet and legs.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Neuroendocrine Tumor?
Treatment for neuroendocrine tumors depends on the type and location, as well as whether the tumor is producing excess hormones. Treatment for endocrine tumors may include surgery; chemotherapy; targeted drug therapy, such as everolimus and sunitinib; immunotherapy, such as interferon alfa-2b; peptide receptor radionuclide therapy; somatostatin analogs, such as octreotide and lanreotide; radiation therapy; radiofrequency ablation; and hepatic artery embolization.
Who are the top Neuroendocrine Tumor Local Doctors?
James C. Yao
Elite in Neuroendocrine Tumor
Dr. James C. Yao
Oncology
Elite in Neuroendocrine Tumor
Dr. James C. Yao
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

James Yao is an Oncologist in Houston, Texas. Dr. Yao is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Metastatic Insulinoma, Carcinoid Syndrome, and Pancreatectomy.

Elite in Neuroendocrine Tumor
Dr. Matthew H. Kulke
Oncology
Elite in Neuroendocrine Tumor
Dr. Matthew H. Kulke
Oncology
720 Harrison Ave, 
Boston, MA 
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Kulke is an Oncologist in Boston, Massachusetts. Dr. Kulke is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Carcinoid Syndrome, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Liver Embolization. Dr. Kulke is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neuroendocrine Tumor
Dr. Daneng F. Li
Oncology
Elite in Neuroendocrine Tumor
Dr. Daneng F. Li
Oncology

City Of Hope Medical Foundation

1500 E Duarte Rd, 
Duarte, CA 
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daneng Li is an Oncologist in Duarte, California. Dr. Li has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Lymphadenectomy, and Colonoscopy.

View All Doctors
What are the latest Neuroendocrine Tumor Clinical Trials?
NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours
NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Drug
Study Phase: Phase 2

Summary: This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have previously received 177Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumor (GEPNET) that has spread from where it first started (primary site) to other places in the body (...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Cancer Moonshot Biobank Research Protocol
Cancer Moonshot Biobank Research Protocol
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Other

Summary: This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The Cancer Moonshot Biobank is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better underst...

View All Clinical Trials